Abstract:Previous studies have indicated that the overexpression of NOK, also named STYK1, led to tumorigenesis and metastasis. Here, we provide evidence that increased expression of NOK/STYK1 caused marked alterations in the overall and inner structures of tumors and substantially facilitates the genesis and remodeling of the blood and lymphatic vessels during tumor progression. In particular, NOK-expressed HeLa stable cells (HeLa-K) significantly enhanced tumor growth and metastasis in xenografted nude mice. Hematoxylin and eosin (HE) staining demonstrated that the tumor tissues generated by HeLa-K cells were much more ichorous and had more interspaces than those generated by control HeLa cells (HeLa-C). The fluorescent areas stained with cluster of differentiation 31 (CD31), a marker protein for blood vessels, appeared to be in different patterns. The total blood vessels, especially the ring patterns, within the tumors of the HeLa-K group were highly enriched compared with those in the HeLa-C group. NOK-HA was demonstrated to be well colocalized with CD31 in the wall of the tubular structures within tumor tissues. Interestingly, antibody staining of the lymphatic vessel endothelial hyaluronan receptor (LYVE-1) further revealed the increase in ring (oratretic strip-like) lymphatic vessels in either the peritumoral or intratumoral areas in the HeLa-K group compared with the HeLa-C group. Consistently, the analysis of human cancerous tissue also showed that NOK was highly expressed in the walls of tubular structures. Thus, our results reveal a novel tumorigenic function of NOK to mediate the genesis and remodeling of blood and lymphatic vessels during tumor progression.

Nok Activates Stat3 Signaling by A Jak2-Dependent Mechanism

NOK Associates with C-Src and Promotes C-Src-induced STAT3 Activation and Cell Proliferation.

Nok Interacts With Akt And Enhances Its Activation

Transmembrane Helix of Novel Oncogene with Kinase-Domain (NOK) Influences Its Oligomerization and Limits the Activation of RAS/MAPK Signaling

NOK/STYK1 Interacts with GSK-3β and Mediates Ser9 Phosphorylation Through Activated Akt

NOK promotes tumorigenesis through coordinating epidermal growth factor receptor to boost the downstream signaling in breast cancer

The Carboxyl Terminal Tyrosine 417 Residue of Nok Has an Autoinhibitory Effect on Nok-Mediated Signaling Transductions

A Novel Protein Tyrosine Kinase Nok That Shares Homology With Platelet-Derived Growth Factor/Fibroblast Growth Factor Receptors Induces Tumorigenesis And Metastasis In Nude Mice

High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.

Point Mutation at Single Tyrosine Residue of Novel Oncogene Nok Abrogates Tumorigenesis in Nude Mice

NOK/STYK1 Has a Strong Tendency Towards Forming Aggregates and Colocalises with Epidermal Growth Factor Receptor in Endosomes

NOK/STYK1 Promotes the Genesis and Remodeling of Blood and Lymphatic Vessels During Tumor Progression

Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

Generation and application of the NOK/STYK1 monoclonal antibody

Effect of NOK Over-expression on Proliferation of Lung Adenocarcinoma Cell A549

Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer

Phosphoproteomic Analysis of Anaplastic Lymphoma Kinase (alk) Downstream Signaling Pathways Identifies Signal Transducer and Activator of Transcription 3 As A Functional Target of Activated Alk in Neuroblastoma Cells

Preclinical Characterization of WB737, a Potent and Selective STAT3 Inhibitor, in Natural Killer/t-Cell Lymphoma

NDR1/STK38 potentiates NF-κB activation by its kinase activity.

The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation

The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma